<DOC>
	<DOCNO>NCT00700193</DOCNO>
	<brief_summary>The purpose study determine Safety , Tolerability &amp; Immunogenicity CSL Limited 's Influenza Virus Vaccine two dose primary vaccination series , 12-month booster vaccination , paediatric population equal great 6 month le 9 year old .</brief_summary>
	<brief_title>A Study Safety , Tolerability &amp; Immunogenicity CSL Limited 's Influenza Virus Vaccine In Paediatric Population</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Be healthy male female child , age = &gt; 6 month &lt; 9 year time first study vaccination ; Note : = &gt; 6 refers 6 calendar month 2 . Parent ( ) Guardian ( ) provide write informed consent participate study ; 3 . Be able provide prevaccination sample 5mL venous blood without undue distress/discomfort 4 . Be bear normal gestation period ( 36 42 week ) . 1 . Known allergy egg , chicken feather , neomycin , polymyxin , component vaccine ; 2 . Previous influenza vaccination ; 3 . Clinical sign active infection and/or axillary temperature = &gt; 37.5 degree Celsius oral temperature = &gt; 38 degree Celsius study entry . Study entry may defer individual , discretion Principal Investigator ; 4 . Confirmed suspected immunosuppressive condition ( include cancer ) , previously diagnose ( congenital acquire ) immunodeficiency disorder ( include HIV ) ; 5 . Current ( within 90 day prior receive Study Vaccine ) treatment immunosuppressive immunomodulative medication , include systemic corticosteroid , follow : •Chronic long term corticosteroid : &gt; 0.5mg/kg/day oral prednisolone equivalent ( Note : Use topical inhalant corticosteroid prior administration Study Vaccine throughout Study acceptable ) . 6 . Administration immunoglobulins and/or blood product since birth plan administration blood product study period ; 7 . Participation clinical study use investigational compound ( ie new chemical biological entity register clinical use ) , within 90 day prior receive Study Vaccine planning enter study study period ; 8 . Current treatment cytotoxic drug treatment within 6 month prior administration Study Vaccine ; 9 . Have know history GuillainBarré Syndrome ; 10 . Have major congenital defect serious illness 11 . Have history neurologic disorder seizure</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>